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Verrier et al. (1) review the evidence regarding clinical utility of
microvolt T-wave alternans (MTWA) testing, suggesting that it
may be used to identify patients at risk of life-threatening
ventricular arrhythmias. In light of conflicting results from recent
clinical studies, an overview for the practicing clinician is much
needed. However, there are important issues that are not ad-
dressed.
In their review, the authors do not mention that patients with
atrial fibrillation, which is highly prevalent in heart failure (10% to
50%) (2), are unsuitable for spectral MTWA testing. Furthermore,
exercise intolerance and continuous ventricular pacing also pre-
clude MTWA testing. Even if MTWA was demonstrated to
improve risk stratification, alternative strategies would be required
for the significant proportion of ineligible patients.
The authors also admit that MTWA is not consistently pre-
dictive of arrhythmic events in patients with an implanted
cardioverter-defibrillator (ICD), suggesting 2 possible explana-
tions for this anomaly: use of appropriate ICD discharge as an
endpoint, and differences in beta-blocker use. However, the
possibility that MTWA does not accurately predict ventricular
arrhythmias is not addressed. The authors correctly point out that
an appropriate ICD discharge is not a surrogate for sudden cardiac
death, but do not acknowledge that it is a more accurate record of
ventricular arrhythmias than can be obtained in patients without
ICDs. If MTWA cannot accurately predict ventricular arrhyth-
mias, then it follows that it cannot predict ICD benefit. Indeed,
Verrier et al. (1) acknowledge that MTWA has no utility in
guiding therapy.
Despite the fundamental deficiencies in the evidence base for
MTWA as a risk stratification tool, and their clear statement thatit cannot be used to guide therapy, the authors conclude that it is
reasonable to consider MTWA testing in patients at risk of lethal
arrhythmias. This is inappropriate in a clinical guideline. It is not
economical, potentially harmful, and therefore unethical to subject
patients to a futile investigation that can have no influence on their
subsequent management. With the currently available evidence,
MTWA cannot be endorsed as having any role in identifying
patients at high risk of a lethal arrhythmia who may benefit from
an ICD. The alternative strategy of using a negative MTWA test
to identify patients unlikely to benefit from an ICD requires
testing in a prospective study. Arrhythmia risk stratification
remains challenging, and efforts to optimize our approach must
continue, but until evidence demonstrates that MTWA results are
clinically meaningful, then we believe that its use, other than in
clinical research, is not reasonable and should not be encouraged.
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